Lori Macomber joined Legend Biotech in September 2019, since serving as vice president of finance, vice president of supply chain finance and controller, and principal financial and accounting officer.
On May 9, the Somerset-based biotech company announced Macomber’s promotion to chief financial officer, effective immediately. She assumes the role from Ying Huang, who has served as both CFO and CEO since September 2020.
“Lori is a highly valued leader and strategic thought partner that has been instrumental in building the company’s finance organization,” Huang — who will continue to serve as CEO — said in a statement. “Lori possesses deep financial and accounting expertise and the operational experience needed to usher the company toward sustainable growth as we become a fully commercial organization and help create long-term value for all of our stakeholders.”
Along with her promotion, which will find her leading the company’s financial operations, Macomber will retain her responsibilities as principal financial and accounting officer.
Before joining Legend, Macomber served as business unit controller at Ametek PDS, an aerospace and defense industry supplier. She has also held various senior finance and accounting roles in the life sciences industry, including as U.S. CFO and controller of Cello Heath and assistant vice president finance site leader at Eli Lilly & Co.
Macomber holds a bachelor’s degree in accounting from Penn State and is a certified public accountant.
Legend Biotech has three R&D sites around the world is focused on developing advanced cell therapies across an array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor, and natural killer cell-based immunotherapy.